NCT00064636View on ClinicalTrials.gov

Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 31, 2002

Conditions
Advanced Non-Small Cell Lung CancerOther Solid Tumors
Interventions
DRUG

VELCADE TM (bortezomib) for Injection, or PS-341

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT00064636 - Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | Biotech Hunter | Biotech Hunter